CONCLUSIONS	The use of the European Organization for Research and Treatment of Cancer QLQ C30 +3 and trial-specific checklist was able to assess the effect of expected toxicities on patient ' s QOL during and following treatment , and so may be useful in addressing the concerns regarding methodological issues that have limited the acquisition of prospective , longitudinal treatment-related toxicity data .\